Amino Triazolopyrimidine A2A/A2B Antagonists for Tumor-Selective Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments have not effectively addressed the challenges of cancer immunotherapy by targeting the A2a and/or A2b receptor inhibitors alone or in combination with other therapeutic agents designed to treat cancer.
Innovation Solution
The development of compounds that inhibit the adenosine A2a and/or A2b receptors, which are administered alone or in combination with other therapeutic agents to treat cancer and immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adenosine A2a and A2b receptor antagonists are used to enhance anti-tumor immune responses, then cancer treatment effectiveness is improved, but potential side effects on normal immune cells and tissues may worsen
Solution Approach 1:
The patent applies local quality by developing receptor antagonists with selective binding characteristics that preferentially target A2a and A2b receptors in the tumor microenvironment over other adenosine receptors in normal tissues. This selectivity allows the compounds to enhance anti-tumor immunity while minimizing off-target effects on normal immune cells, thereby resolving the contradiction between treatment effectiveness and side effect profile.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure of adenosine receptor antagonists to optimize binding affinity and selectivity. By adjusting molecular parameters such as substituent groups and stereochemistry, the compounds achieve enhanced specificity for A2a/A2b receptors in cancer cells while reducing binding to A1 and A3 receptors in normal tissues, thus improving the therapeutic index.
2Ease of operation
If adenosine A2a and A2b receptor antagonists are administered alone, then treatment simplicity is maintained, but therapeutic efficacy may be insufficient compared to combination therapies
Solution Approach 1:
The patent applies universality by designing A2a/A2b receptor antagonists that can function effectively as monotherapy or in combination with other cancer treatments. The compounds exhibit multi-functional activity by simultaneously blocking adenosine-mediated immunosuppression and enhancing T-cell responses, allowing them to maintain therapeutic efficacy whether used alone or in combination therapies, thus resolving the contradiction between treatment simplicity and efficacy.
3Loss of time
If existing adenosine receptor antagonists are used, then development time is reduced, but potency and selectivity may be insufficient for optimal cancer immunotherapy
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the chemical parameters of adenosine receptor antagonists to achieve superior potency and selectivity. Through structure-activity relationship analysis and medicinal chemistry modifications, the compounds demonstrate enhanced binding affinity to A2a/A2b receptors and improved discrimination against other adenosine receptor subtypes, thereby resolving the contradiction between development time and therapeutic quality.
Solution Approach 2:
The patent utilizes composite materials by integrating multiple pharmacological activities into a single molecular structure. The A2a/A2b receptor antagonists combine properties of adenosine binding, immunomodulation, and T-cell activation in one compound class, achieving optimal potency and selectivity without requiring multiple separate agents, thus maintaining efficient development timelines.
Data Source
AI summary
In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R1, n, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.